Irinotecan Combined with Co-Stimulatory Molecule Blockade Prolongs Survival of Cardiac Allografts in Alloantigen-Primed Mice

•Irinotecan plus anti-LFA-1/CD154 combination was tested on allograft survival in mice.•The combined treatment prevents graft rejection accelerated by alloantigen priming.•Th1 immunity and memory T cell function are inhibited by the combination therapy.•This combination increases secretion of IL-10/TGF-β and regulatory T cell generation.